CPRX - Catalyst Pharmaceuticals, Inc.
Chart Events
Double Moving Average Crossover
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 11.55 |
| Open | 11.45 |
| Bid | 11.56 x 1100 |
| Ask | 11.57 x 1300 |
| Day's Range | 11.09 - 11.65 |
| 52 Week Range | 6.15 - 22.11 |
| Volume | |
| Avg. Volume | 1,944,252 |
| Market Cap | 1.224B |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | 12.96 |
| EPS (TTM) | 0.89 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.40 |
Fair Value
Related Research
ZacksWall Street Analysts See Catalyst (CPRX) as a Buy: Should You Invest?
Based on the average brokerage recommendation (ABR), Catalyst (CPRX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
GlobeNewswireCatalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
Reaffirms Full Year 2023 Total Revenue Guidance of Between $375 Million and $385 Million Forecasts FIRDAPSE® 2023 Net Product Revenue Guidance of Between $245 Million and $255 Million, an Increase of 17% YoY Forecasts FYCOMPA® 2023 Net Product Revenue of Approximately $130 Million for 11 Months Reaffirms Full Year 2023 Non-GAAP Net Income Forecast of Between $195 Million and $205 Million CORAL GABLES, Fla., June 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company"
- GlobeNewswire
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced the appointment of Ms. Tamar Thompson to the Company's Board of Directors ("Board"), effective on May 25, 2023. "We are extremely pleased to welcome Tamar to our Board as she brings a wealth of experi
Motley FoolDown 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy?
In the last 30 days, shares of Catalyst Pharmaceuticals (NASDAQ: CPRX) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. As you might be guessing, the culprit for the tumble was the company's abysmal performance in Q1, which saw its revenue leap upward by 98% year over year, and its earnings per share balloon to the tune of 117%. In truth, the reason for Catalyst's share price collapse is quite simple, even if it's a touch frustrating for those who plan to hold the stock for the long term, like myself.
ZacksShould You Invest in Catalyst (CPRX) Based on Bullish Wall Street Views?
Based on the average brokerage recommendation (ABR), Catalyst (CPRX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Simply Wall St.Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) high institutional ownership speaks for itself as stock continues to impress, up 5.5% over last week
Key Insights Institutions' substantial holdings in Catalyst Pharmaceuticals implies that they have significant...
ZacksCatalyst Pharmaceutical (CPRX) Misses Q1 Earnings Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of -13.33% and 2.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year
Reports Record Total Revenues of $85.4 Million for Q1 2023 Delivers Revenue Growth of 98%, a Record Increase YoY GAAP EPS Diluted of $0.26 Per Share; a 117% Increase YoY Non-GAAP EPS Diluted of $0.41 Per Share, an Increase of 128% YoY Affirms Full Year Total Revenue Guidance of Between $375 Million and $385 Million Forecasts Full-Year 2023 Non-GAAP Net Income of Between $195 Million and $205 Million FYCOMPA® Commercial and Medical Affairs Teams Onboard and Fully Engaged Recently Reported Positiv
- GlobeNewswire
Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day
Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 CORAL GABLES, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported that it recently concluded a Type C meeting with the U.S. Food and Drug Adm
ZacksCatalyst Pharmaceutical (CPRX) Stock Moves -0.12%: What You Should Know
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $16.60, moving -0.12% from the previous trading session.
- GlobeNewswire
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
CORAL GABLES, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases today announced the release of its inaugural Environmental, Social, and Governance Report ("ESG Report"). The inaugural ESG Report provides stakeholders with transparency on the Company's practices across issues withi
ZacksCatalyst Pharmaceutical (CPRX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $15.76, marking a -1.62% move from the previous day.
Zacks3 Reasons Growth Investors Will Love Catalyst (CPRX)
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.
ZacksCatalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know
Catalyst Pharmaceutical (CPRX) closed at $16.52 in the latest trading session, marking a +0.24% move from the prior day.
- GlobeNewswire
Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023
The Company Will Host a Conference Call and Webcast on May 11, 2023, at 8:30 AM ETCORAL GABLES, Fla., April 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its first-quarter 2023 financial results after market close on Wednesday, May 10, 2023. Catalyst’s managemen
- Simply Wall St.
We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- GlobeNewswire
Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting
CORAL GABLES, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that four abstracts highlighting FYCOMPA® (perampanel) CIII have been published and will be presented at the upcoming AAN 2023 Annual Meeting taking place in Boston, MA and virtually
ZacksCatalyst (CPRX) Up 14.1% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksRelay Therapeutics, Inc. (RLAY) Surges 13.8%: Is This an Indication of Further Gains?
Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
ZacksCatalyst Pharmaceutical (CPRX) Flat As Market Sinks: What You Should Know
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $17.55, making no change from the previous trading session.
- Zacks
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
InvestorPlace7 A-Rated Stocks to Buy for April 2023
The first quarter’s in the books, and happily, the stock market is having a much better year than we endured in 2022. If you’re an investor looking for stocks to buy, you’re probably feeling pretty good about your chances for a good April. The Dow Jones Industrial Average is up 1% for the year but has been building much-needed momentum over the last several weeks. The S&P 500 is up 6% in 2023, and the tech-heavy Nasdaq composite shows a 14% gain. But this isn’t the time to stand pat. The world’s
Motley Fool2 Top Growth Stocks That Can Withstand an Economic Downturn
With fresh signs coming out Tuesday that the U.S. economy is starting to slow in response to rising interest rates, growth stocks could be in for a tough second quarter. There are a few growth stocks that are more than capable of generating healthy returns even in a recession. Catalyst Pharmaceuticals (NASDAQ: CPRX) has been on a five-year bull run.
- Zacks
Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $16.78, marking a -0.94% move from the previous day.
Motley Fool1 Growth Stock to Buy Before the Next Bull Market
Biotech Catalyst Pharmaceuticals (NASDAQ: CPRX) is one good candidate. Until early 2023, Catalyst had only one medicine on the market, Firdapse, which treats a rare neuromuscular disease called Lambert-Eaton myasthenic syndrome (LEMS). As a result, Firdapse could bring in as much as $255 million in 2023.
